Quercetin improves postischemic recovery of heart function in doxorubicin-treated rats and prevents doxorubicin-induced matrix metalloproteinase-2 activation and apoptosis induction

International Journal of Molecular Sciences

Volumn 16, Issue 4, 2015, Pages 8168-8185

  Barteková, Monika ^a   Šimončíková, Petra ^a   Fogarassyová, Mária ^a   Ivanová, Monika ^a   Okruhlicová, L’udmila ^a   Tribulová, Narcisa ^a   Dovinová, Ima ^a   Barančík, Miroslav ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Cell signaling; Doxorubicin; Heart; Ischemic tolerance; Matrix metalloproteinases; Quercetin

Indexed keywords

CASPASE 3; CONNEXIN 43; DOXORUBICIN; GELATIN; GELATINASE A; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MUSCLE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; QUERCETIN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ULTRASTRUCTURE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION ASSAY; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PROTECTION; HEART RATE; INTRACELLULAR SIGNALING; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC BLOOD PRESSURE; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE; METABOLISM; REPERFUSION INJURY; WISTAR RAT;

RATTUS;

ANIMALS; APOPTOSIS; BLOOD PRESSURE; CONNEXIN 43; DOXORUBICIN; HEART VENTRICLES; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; RATS; RATS, WISTAR; REPERFUSION INJURY; SUPEROXIDE DISMUTASE; UP-REGULATION;

EID: 84927930734     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16048168     Document Type: Article

References (38)

1. Hertog, M.G.; Bueno-de-Mesquita, H.B.; Fehily, A.M.; Sweetnam, P.M.; Elwood P.C.; Kromhout, D. Fruit and vegetable consumption and cancer mortality in the Caerphilly Study. Cancer Epidemiol. Biomark. Prev. 1996, 5, 673-677.
2. Erden Inal, M.; Kahraman, A. The protective effect of flavonol quercetin against ultraviolet a induced oxidative stress in rats. Toxicology 2000, 154, 21-29.
3. Wu J.; Xu, X.; Li, Y.; Kou, J.; Huang, F.; Liu, B.; Liu, K. Quercetin, luteolin and epigallocatechin gallate alleviate TXNIP and NLRP3-mediated inflammation and apoptosis with regulation of AMPK in endothelial cells. Eur. J. Pharmacol. 2014, 745, 59-68.
4. Yu P.X.; Zhou, Q.J.; Zhu, W.W.; Wu, Y.H.; Wu, L.C.; Lin, X.; Chen, M.H.; Qiu, B.T. Effects of quercetin on LPS-induced disseminated intravascular coagulation (DIC) in rabbits. Thromb. Res. 2013, 131, 270-273.
5. Duarte, J.; Perez-Palencia, R.; Vargas, F.; Ocete, M.A.; Perez-Vizcaino, F.; Zarzuelo, A.; Tamargo, J. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br. J. Pharmacol. 2001, 133, 117-124.
6. Sanchez, M.; Galisteo, M.; Vera, R.; Villar, I.C.; Zarzuelo, A.; Tamargo, J.; Pérez-Vizcaíno, F.; Duarte, J. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. 2006, 24, 75-84.
7. Yamamoto, Y; Oue, E. Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet. Biosci. Biotechnol. Biochem. 2006, 70, 933-939.
8. Jin, H.B.; Yang, Y.B.; Song, Y.L.; Zhang, Y.C.; Li, Y.R. Protective roles of quercetin in acute myocardial ischemia and reperfusion injury in rats. Mol. Biol. Rep. 2012, 39, 11005-11009.
9. Bartekova, M.; Carnicka, S.; Pancza, D.; Ondrejcakova, M.; Breier, A.; Ravingerova, T. Acute treatment with polyphenol quercetin improves postischemic recovery of isolated perfused rat hearts after global ischemia. Can. J. Physiol. Pharmacol. 2010, 88, 465-471.
10. Annapurna, A.; Reddy, C.S.; Akondi, R.B. Rao, S.R. Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin-induced type I diabetic rats. J. Pharmacy Pharmacol. 2009, 61, 1365-1374.
11. Milton Prabu, S; Muthumani, M.; Shagirtha, K. Quercetin potentially attenuates cadmium induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 582-595.
12. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
13. Arola, O.J.; Saraste, A.; Pulkki, K.; Kallajoki, M.; Parvinen, M.; Voipio-Pulkki, L.M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000, 60, 1789-1792.
14. Singal, P.K.; Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339, 900-905.
15. Gharanei, M.; Hussain, A.; Janneh, O.; Maddock, H.L. Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore. Toxicol. Appl. Pharmacol. 2013, 268, 149-156.
16. Simoncíkova, P.; Ravingerova T.; Barancik, M. The effect of chronic doxorubicin treatment on mitogen-activated protein kinases and heat stress proteins in rat hearts. Physiol. Res. 2008, 57, S97-S102.
17. Mackraj, I.; Govender, T.; Ramesar, S. The antihypertensive effects of quercetin in a salt-sensitive model of hypertension. J. Cardiovasc. Pharmacol. 2008, 51, 239-245.
18. Rendig, S.V.; Symons, J.D.; Longhurst, J.C.; Amsterdam, E.A. Effects of red wine, alcohol, and quercetin on coronary resistance and conductance arteries. J. Cardiovasc. Pharmacol. 2001, 38, 219-227.
19. Adamcová, M.; Potacova, A.; Popelova, O.; Sterba, M.; Mazurova, Y.; Aupperle, H.; Geršl, V. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol. Res. 2010, 59, 831-836.
20. Ivanova, M.; Dovinova, I.; Okruhlicová, L.; Tribulova, N.; Simoncíkova, P.; Bartekova, M.; Vlkovicova, J.; Barancik, M. Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats. Acta Pharmacol. Sin. 2012, 33, 459-469.
21. Bai, P.; Mabley, J.G.; Liaudet, L.; Virag, L.; Szabo, C.; Pacher, P. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol. Rep. 2004, 11, 505-508.
22. Okamoto, T; Akaike, T.; Sawa, T.; Miyamoto, Y.; van derVliet, A.;. Maeda, H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 2001, 276, 29596-29602.
23. Schulz, R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approaches. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 211-242.
24. Viappiani, S.; Nicolescu, A.C.; Holt, A.; Sawicki, G.; Crawford, B.D.; Leon, H.; van Mulligen, T.; Schulz, R. Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem. Pharmacol. 2009, 77, 826-834.
25. Kowluru, R.A.; Kanwar, M. Oxidative stress and the development of diabetic retinopathy: Contributory role of matrix metalloproteinase-2. Free Radic. Biol. Med. 2009, 46, 1677-1685.
26. Hausenloy, D.J.; Mocanu, M.M.; Yellon, D.M. Cross-talk between the survival kinases during early reperfusion: Its contribution to ischemic preconditioning. Cardiovasc. Res. 2004, 63, 305-312.
27. Strniskova, M.; Ravingerova, T.; Neckar, J.; Kolar, F.; Pastorekova, S.; Barancik, M. Changes in the expression and/or activation of regulatory proteins in rat hearts adapted to chronic hypoxia. Gen. Physiol. Biophys. 2006, 25, 25-41.
28. Ravingerova, T.; Matejikova, J.; Neckar, J.; Andelova, E.; Kolar, F. Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart. Mol. Cell. Biochem. 2007, 297, 111-120.
29. Matsui, T.; Tao, J.; del Monte, F.; Lee, K.H.; Li, L.; Picard, M.; Force, T.L.; Franke, T.F.; Hajjar, R.J.; Rosenzweig, A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001, 104, 330-335.
30. Miura, T.; Tanno, M.; Sato, T. Mitochondrial kinase signaling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis. Cardiovasc. Res. 2010, 88, 7-15.
31. Budas, G.R.; Sukhodub, A.; Alessi, D.R.; Jovanovic, A. 3' Phosphoinositidedependent kinase-1 is essential for ischemic preconditioning of the myocardium. FASEB J. 2006, 20, 2556-2558.
32. Yin, Z.; Gao, H.; Wang, H.; Li, L.; Di, C.; Luan, R.; Tao, L. Ischemic postconditioning protects both adult and aged Sprague Dawley rat hearts from ischemia/reperfusion injury through the PI3-K/Akt and GSK-3β pathway. Clin. Exp. Pharmacol. Physiol. 2009, 36, 756-763.
33. Ding, V.W.; Chen, R.H.; McCormick, F. Differential regulation of glycogen synthase kinase 3β by insulin and Wnt signaling. J. Biol. Chem. 2000, 275, 32475-32481.
34. Issan, Y.; Kornowski, R.; Aravot, D.; Shainberg, A.; Laniado-Schwartzman, M.; Sodhi, K.; Abraham, N.G.; Hochhauser, E. Heme oxygenase-1 induction improves cardiac function following myocardial ischemia by reducing oxidative stress. PLoS ONE 2014, 21, e92246.
35. Srisakuldee, W.; Jeyaraman, M.M.; Nickel, B.E.; Tanguy, S.; Jiang, Z.S.; Kardami, E. Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state. Cardiovasc. Res. 2009, 83, 672-681.
36. Garcia-Dorado, D.; Rodriguez-Sinovas, A.; Ruiz-Meana, M. Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion. Cardiovasc. Res. 2004, 61, 386-401.
37. Zhang, H.; Zhang, A.; Guo, C.; Shi, C.; Zhang, Y.; Liu, Q.; Sparatore, A; Wang, C. S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. PLoS ONE 2011, 6, e26441.
38. Bradford, M. A rapid and sensitive method for the quantitation of microgram quanties of protein utilizing the principle of protein-dye-binding. Anal. Biochem. 1976, 72, 248-254.